Daiichi Sankyo was on the receiving end of an FDA slapdown more than two years ago for FLT3 drug quizartinib and some flimsy data in acute myeloid leukemia. Looking to salvage a bad situation, Daiichi…
NK cell biotech Cytovia and gene editing firm Cellectis are expanding upon their previous team-up. The two biotechs announced yesterday they have expanded their collaboration of gene-edited, iPSC…
A suite of drugmakers is looking to topple Dupixent in the eczema market — and on Thursday, China-based Connect Biopharma uncorked some mid-stage results it says will pave the way to a pivotal trial.…
In a surprise setback, Merck has slammed the brakes on the development of an experimental HIV drug — including a Phase II trial — after investigators flagged a drop in immune cell counts that an…
The European Medicines Agency on Friday said that Merck’s antiviral molnupiravir can now be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of…
The FDA on Friday signed off on an accelerated approval for Biomarin’s Voxzogo (vosoritide) injection, the first treatment to target the underlying genetics of dwarfism, which can increase the height…
Last week, Bristol Myers Squibb marched out long-term data for its heart drug mavacamten ahead of what execs had hoped would be a positive FDA decision in January. But regulators are saying they need…
All US adults who received two doses of an mRNA Covid-19 vaccine are now eligible for a booster shot, the FDA announced Friday. The moves will amend the existing EUAs for the Pfizer/BioNTech and…
Touting its mission to revolutionize R&D by bringing drug development into the cloud, Benchling has earned its unicorn horn from investors hungry for something new. A new round of financing will now…
BridgeBio Pharma and Helsinn are tightening their ties. Having teamed up to develop one drug in March, the partners have decided to work together on more prospects, starting with a potentially first…
